Arteris, INC Form 4 insider transactions

Arteris Inc. Chief Operating Officer Moll Laurent R reported the sale of common stock under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. (AIP) reports a Form 4 filing detailing the sale of common stock by President and CEO K. Charles Janac, executed under a pre-established 10b5-1 trading plan.

Bayview Legacy, LLC, controlled by K. Charles Janac, reported the sale of 70,000 shares of Arteris, Inc. common stock for approximately $19.04 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Joachim Kunkel acquired 899 shares of common stock as retainer fees, valued at $15.98 per share.

Arteris, Inc. Director Claudia F. Munce acquired 860 shares of common stock as fully vested restricted stock, representing retainer fees elected in lieu of cash.

Arteris Inc. VP and CFO Nicholas B. Hawkins sold company stock to cover tax liabilities from restricted stock unit releases.

Arteris, Inc. Chief Operating Officer Moll Laurent R has reported the sale of company shares to cover tax obligations and transactions made under a pre-arranged trading plan.

Arteris Inc. President and CEO K. Charles Janac reported the sale of common stock to cover tax liabilities related to restricted stock unit releases, with some transactions executed under a 10b5-1 plan.

Arteris Inc. VP and General Counsel Paul L. Alpern reported the sale of common stock to cover tax withholding obligations arising from restricted stock unit releases.

Arteris, Inc. President and CEO K. Charles Janac sold 40,000 shares of common stock in late March 2026 through a pre-arranged 10b5-1 trading plan.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., sold 40,000 shares of common stock over two days in late March 2026 under a pre-arranged 10b5-1 trading plan.

An Arteris, Inc. director sold 109,721 shares of common stock in early March 2026 through a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Saiyed Atiq Raza sold 90,279 shares of common stock across three transactions in late February 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Bayview Legacy, a 10% owner of Arteris, Inc., reported a planned gift of 70,000 shares of common stock effective February 20, 2026, under a Rule 10b5-1 plan.

Arteris, Inc. Chief Operating Officer Laurent R. Moll received a grant of 37,553 restricted stock units, aligning executive interests with shareholder value.

Arteris, Inc. CFO Nicholas B. Hawkins was granted 41,217 restricted stock units, vesting quarterly starting April 1, 2026, under a Rule 10b5-1 plan.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, was granted 32,385 restricted stock units, vesting quarterly starting April 1, 2026.

Arteris, Inc. President and CEO Charles Janac disclosed an acquisition of restricted stock units and a gift of common stock.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., sold a total of 50,000 shares of common stock in pre-planned transactions.

Arteris, Inc. President and CEO, Janac K. Charles, reported the sale of common stock totaling 50,000 shares under a Rule 10b5-1 trading plan.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, exercised options and sold 5,000 shares of common stock for a significant gain under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, Janac K Charles, sold 17,884 shares of common stock for approximately $17.84 per share under a pre-arranged 10b5-1 trading plan.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported the sale of 17,884 common shares at a weighted average price of $17.8357 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, Janac K Charles, sold 2,116 shares of common stock for $17.7901 per share under a pre-arranged 10b5-1 trading plan.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported the sale of 2,116 shares of common stock at a weighted average price of $17.7901 per share.

Arteris, Inc. President and CEO, K. Charles Janac, sold 50,000 shares of common stock on January 8, 2026, through a pre-arranged 10b5-1 trading plan.

Bayview Legacy, LLC, a 10% owner and entity controlled by a director, reported the sale of 50,000 shares of Arteris, Inc. common stock under a 10b5-1 plan.

Arteris, Inc.'s VP and CFO, Nicholas B. Hawkins, sold 5,836 shares of common stock for a weighted average price of $17.272 per share under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, K. Charles Janac, reported the sale of 11,145 shares of common stock for approximately $188,380 under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Chief Operating Officer Laurent R. Moll reported the sale of 1,420 shares of common stock at $16.23 per share, executed under a pre-arranged 10b5-1 trading plan.